newsfilter
← Earnings
Earnings Releases·

MetaVia — Third Quarter 2026 Earnings Summary

MetaVia Inc. reported a net loss of $4.6 million for the third quarter of 2026, driven by increased research and development expenses related to its lead candidate DA-1726. The company announced positive interim data from a Phase 1 study showing a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss, supporting plans for a Phase 2 trial in MetALD and ALD expected to begin in late 2027. Additionally, MetaVia appointed Sarah Browne, M.D., as Chief Medical Officer to lead clinical development while advancing its second candidate, vanoglipel, in combination with resmetirom for MASH.

Company
METAVIA INC
Sector
Healthcare
Industry
Biotechnology